PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
July 5, 2026Journal of Clinical Medicine0 citationsOpen Access

Three- and Nine-Month Follow-Up of Patients with COVID-19: Clinical, Functional, and Radiological Outcomes

View Full Paper
MDMuhammed DegerTKTalat KılıçZUZeynep Ulutaş

Key Points

  • This study aimed to evaluate the long-term complications of COVID-19 at 3 and 9 months after infection.
  • Conducted at Inonu University Turgut Ozal Medical Center, assessing patients post-COVID-19 at 3 and 9 months.
  • Performed pulmonary function tests, six-minute walk tests, echocardiography, and CT scans.
  • Stratified patients based on severity: outpatient, ward-hospitalized, and ICU-hospitalized.
  • 85.3% of patients had at least one persistent symptom at 9 months, with dyspnea (69.6%) being the most common.
  • FVC increased significantly from 3 months to 9 months (p = 0.014), and 6MWT distance improved (423.56 m vs. 464.10 m; p = 0.008).
  • 44.3% of patients experienced persistent ground-glass opacity at 9 months (p < 0.001), with increased reticular opacities and other patterns.

Abstract

Background/Objectives: The acute complications of COVID-19 have been well characterized and are frequently associated with increased mortality. Although substantial knowledge regarding long COVID has accumulated since the beginning of the pandemic, important uncertainties remain regarding the long-term clinical, functional, radiological, and metabolic consequences of SARS-CoV-2 infection. Identification of post-COVID-19 complications is therefore essential for appropriate recognition and management. This study aimed to evaluate the long-term complications of COVID-19 at 3 and 9 months after infection. Methods: This prospective study was conducted at Inonu University Turgut Ozal Medical Center. Patients who presented with active post-COVID-19 complaints or for routine follow-up were enrolled. Participants were evaluated at the pulmonology outpatient clinic at 3 and 9 months. At each visit, persistent or new-onset symptoms were assessed, and pulmonary function tests (PFT), the six-minute walk test (6MWT), echocardiography (ECHO), and thoracic computed tomography (CT) were performed as clinically indicated. Patients were stratified into three groups according to the severity of acute illness: outpatient, ward-hospitalized, and ICU-hospitalized. Results: A total of 205 patients (120 male, 85 female) were included. Male patients had significantly higher rates of ward and ICU hospitalization than female patients (p = 0.006). At 9 months, 85.3% of patients had at least one persistent symptom; dyspnea (69.6%), cough (35.6%), and chest pain (32.5%) were the most common. FVC showed a statistically significant increase between months 3 and 9 (p = 0.014), and the 6MWT distance improved significantly (423.56 m vs. 464.10 m; p = 0.008). Ground-glass opacity, present in 90.2% of patients at admission, persisted in 44.3% at 9 months (p < 0.001). Reticular opacities, pleuroparenchymal bands, and mosaic perfusion patterns increased over time. ICU patients had significantly lower ejection fraction values compared with ward and outpatient groups at 9 months (p = 0.046). During follow-up, 13 patients developed pulmonary embolism and 7 developed new-onset diabetes mellitus. Conclusions: Despite the well-characterized acute phase, the long-term sequelae of COVID-19 remain a significant clinical challenge. Identification of late complications is critical for reducing morbidity and understanding the long-term societal and healthcare burden of the pandemic. Multidisciplinary long-term follow-up is warranted, particularly for patients who experienced severe acute illness.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Deger et al. (2026) studied this question.

synapsesocial.com/papers/6a49f4b8f5d1d45b28800064https://doi.org/10.3390/jcm15135202
Ask AI
Helpful
Bookmark
Share
View Full Paper